[96a5a0]: / output / allTrials / identified / NCT05890872_identified.json

Download this file

514 lines (514 with data), 24.3 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
{
"info": {
"nct_id": "NCT05890872",
"official_title": "A Clinical Study of Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced Cancer",
"inclusion_criteria": "* Patient has suspected or confirmed metastatic cancer within the lungs, or stage IV non-small cell lung cancer (NSCLC) requiring biopsy.\n* Patient has radiologically documented suspected, or confirmed tumor(s) that are ≤ 5 cm in longest diameter and deemed by the investigator to be suitable per study procedural guidelines for treatment with PEF.\n* Patient is deemed eligible to receive 1L SOC therapy for their malignancy.\n* In the opinion of the investigator, the patient is not a surgical candidate for curative intent, or the patient has refused surgery.\n* Life expectancy ≥ 6 months.\nHealthy volunteers allowed\nMust have minimum age of 22 Years",
"exclusion_criteria": "* Patient has received any prior cancer therapy for current tumor(s) to be treated with PEF.\n* Patient is scheduled to receive investigational therapies (including device-based therapy) that may interfere with the study endpoints while on this study.\n* Patient has clinical evidence of leptomeningeal disease or brain metastases that require SOC treatment within 4 weeks post-PEF treatment.\n* Patient with active, known, or suspected autoimmune disease.\n* Patient with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Patient has received systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 30 days prior to study enrollment. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.\n* Patient has any history of primary immunodeficiency.\n* Patient has clinical signs or symptoms of active tuberculosis infection.\n* Patient has documented evidence of acute hepatitis or has an active or uncontrolled infection.\n* Patient has undergone major surgery (excluding placement of vascular access) within 28 days prior to study enrollment or has planned major surgeries while enrolled in the study,\n\nOther protocol defined inclusion/exclusion criteria apply",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patient has suspected or confirmed metastatic cancer within the lungs, or stage IV non-small cell lung cancer (NSCLC) requiring biopsy.",
"criterions": [
{
"exact_snippets": "suspected or confirmed metastatic cancer within the lungs",
"criterion": "metastatic cancer within the lungs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"suspected",
"confirmed"
]
}
]
},
{
"exact_snippets": "stage IV non-small cell lung cancer (NSCLC)",
"criterion": "stage IV non-small cell lung cancer (NSCLC)",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "requiring biopsy",
"criterion": "biopsy requirement",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
}
]
},
{
"line": "* Patient has radiologically documented suspected, or confirmed tumor(s) that are ≤ 5 cm in longest diameter and deemed by the investigator to be suitable per study procedural guidelines for treatment with PEF.",
"criterions": [
{
"exact_snippets": "radiologically documented suspected, or confirmed tumor(s)",
"criterion": "tumor presence",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "tumor(s) that are ≤ 5 cm in longest diameter",
"criterion": "tumor size",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "cm"
}
}
]
},
{
"exact_snippets": "deemed by the investigator to be suitable per study procedural guidelines for treatment with PEF",
"criterion": "suitability for PEF treatment",
"requirements": [
{
"requirement_type": "suitability",
"expected_value": true
}
]
}
]
},
{
"line": "* Patient is deemed eligible to receive 1L SOC therapy for their malignancy.",
"criterions": [
{
"exact_snippets": "deemed eligible to receive 1L SOC therapy",
"criterion": "eligibility for 1L SOC therapy",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": true
}
]
},
{
"exact_snippets": "for their malignancy",
"criterion": "malignancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* In the opinion of the investigator, the patient is not a surgical candidate for curative intent, or the patient has refused surgery.",
"criterions": [
{
"exact_snippets": "the patient is not a surgical candidate for curative intent",
"criterion": "surgical candidacy for curative intent",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": false
}
]
},
{
"exact_snippets": "the patient has refused surgery",
"criterion": "surgery refusal",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Life expectancy ≥ 6 months.",
"criterions": [
{
"exact_snippets": "Life expectancy ≥ 6 months.",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "months"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 22 Years",
"criterions": [
{
"exact_snippets": "minimum age of 22 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 22,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patient has received any prior cancer therapy for current tumor(s) to be treated with PEF.",
"criterions": [
{
"exact_snippets": "Patient has received any prior cancer therapy for current tumor(s)",
"criterion": "prior cancer therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patient is scheduled to receive investigational therapies (including device-based therapy) that may interfere with the study endpoints while on this study.",
"criterions": [
{
"exact_snippets": "Patient is scheduled to receive investigational therapies (including device-based therapy)",
"criterion": "investigational therapies",
"requirements": [
{
"requirement_type": "scheduled",
"expected_value": true
}
]
},
{
"exact_snippets": "investigational therapies (including device-based therapy) that may interfere with the study endpoints",
"criterion": "interference with study endpoints",
"requirements": [
{
"requirement_type": "potential",
"expected_value": true
}
]
}
]
},
{
"line": "* Patient has clinical evidence of leptomeningeal disease or brain metastases that require SOC treatment within 4 weeks post-PEF treatment.",
"criterions": [
{
"exact_snippets": "clinical evidence of leptomeningeal disease",
"criterion": "leptomeningeal disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "brain metastases that require SOC treatment",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "treatment requirement",
"expected_value": "SOC treatment"
}
]
}
]
},
{
"line": "* Patient with active, known, or suspected autoimmune disease.",
"criterions": [
{
"exact_snippets": "active, known, or suspected autoimmune disease",
"criterion": "autoimmune disease",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"active",
"known",
"suspected"
]
}
]
}
]
},
{
"line": "* Patient with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.",
"criterions": [
{
"exact_snippets": "type I diabetes mellitus",
"criterion": "type I diabetes mellitus",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "hypothyroidism only requiring hormone replacement",
"criterion": "hypothyroidism",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": "hormone replacement"
}
]
},
{
"exact_snippets": "skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment",
"criterion": "skin disorders",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": "not requiring systemic treatment"
}
]
},
{
"exact_snippets": "conditions not expected to recur in the absence of an external trigger",
"criterion": "conditions not expected to recur",
"requirements": [
{
"requirement_type": "trigger",
"expected_value": "absence of an external trigger"
}
]
}
]
},
{
"line": "* Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.",
"criterions": [
{
"exact_snippets": "Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.",
"criterion": "replacement therapy",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
}
]
},
{
"line": "* Patient has received systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 30 days prior to study enrollment. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.",
"criterions": [
{
"exact_snippets": "Patient has received systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) ... within 30 days prior to study enrollment.",
"criterion": "systemic corticosteroid treatment",
"requirements": [
{
"requirement_type": "dose",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "mg daily prednisone or equivalent"
}
},
{
"requirement_type": "time frame",
"expected_value": "within 30 days prior to study enrollment"
}
]
},
{
"exact_snippets": "Patient has received ... other immunosuppressive medications within 30 days prior to study enrollment.",
"criterion": "immunosuppressive medication treatment",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": "within 30 days prior to study enrollment"
}
]
},
{
"exact_snippets": "Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.",
"criterion": "inhaled or topical steroids",
"requirements": [
{
"requirement_type": "permitted",
"expected_value": true
}
]
},
{
"exact_snippets": "adrenal replacement doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.",
"criterion": "adrenal replacement doses",
"requirements": [
{
"requirement_type": "dose",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "mg daily prednisone or equivalent"
}
},
{
"requirement_type": "permitted",
"expected_value": true
}
]
},
{
"exact_snippets": "in the absence of active autoimmune disease.",
"criterion": "active autoimmune disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patient has any history of primary immunodeficiency.",
"criterions": [
{
"exact_snippets": "any history of primary immunodeficiency",
"criterion": "primary immunodeficiency",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Patient has clinical signs or symptoms of active tuberculosis infection.",
"criterions": [
{
"exact_snippets": "clinical signs or symptoms of active tuberculosis infection",
"criterion": "active tuberculosis infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patient has documented evidence of acute hepatitis or has an active or uncontrolled infection.",
"criterions": [
{
"exact_snippets": "documented evidence of acute hepatitis",
"criterion": "acute hepatitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "active or uncontrolled infection",
"criterion": "infection",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"active",
"uncontrolled"
]
}
]
}
]
},
{
"line": "* Patient has undergone major surgery (excluding placement of vascular access) within 28 days prior to study enrollment or has planned major surgeries while enrolled in the study,",
"criterions": [
{
"exact_snippets": "Patient has undergone major surgery (excluding placement of vascular access) within 28 days prior to study enrollment",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
]
},
{
"exact_snippets": "has planned major surgeries while enrolled in the study",
"criterion": "planned major surgeries",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "Other protocol defined inclusion/exclusion criteria apply",
"criterions": [
{
"exact_snippets": "Other protocol defined inclusion/exclusion criteria apply",
"criterion": "protocol defined inclusion/exclusion criteria",
"requirements": [
{
"requirement_type": "application",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}